-, DOCETAXEL , JDQ443
CJDQ443B12301
Phase 3 small_molecule active
Quick answer
-, DOCETAXEL , JDQ443 for Advanced non-small cell lung cancer harboring the KRAS G12C mutation is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Advanced non-small cell lung cancer harboring the KRAS G12C mutation
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active